Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience

Ann Hematol. 2013 Jan;92(2):263-5. doi: 10.1007/s00277-012-1558-3. Epub 2012 Aug 30.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Benzoates / adverse effects*
  • Benzoates / therapeutic use
  • Chelation Therapy / adverse effects*
  • Child
  • Child, Preschool
  • Deferasirox
  • Deferiprone
  • Female
  • Greece / epidemiology
  • Humans
  • Hypercalciuria / etiology
  • Hyperuricemia / etiology
  • Iron Chelating Agents / adverse effects*
  • Iron Chelating Agents / therapeutic use
  • Iron Overload / drug therapy*
  • Iron Overload / etiology
  • Male
  • Nephrolithiasis / blood
  • Nephrolithiasis / chemically induced*
  • Nephrolithiasis / epidemiology
  • Nephrolithiasis / etiology
  • Postoperative Complications / blood
  • Postoperative Complications / chemically induced
  • Postoperative Complications / epidemiology
  • Postoperative Complications / etiology
  • Pyridones / therapeutic use
  • Splenectomy
  • Transfusion Reaction*
  • Triazoles / adverse effects*
  • Triazoles / therapeutic use
  • Young Adult
  • beta-Thalassemia / blood
  • beta-Thalassemia / complications*
  • beta-Thalassemia / surgery
  • beta-Thalassemia / therapy

Substances

  • Benzoates
  • Iron Chelating Agents
  • Pyridones
  • Triazoles
  • Deferiprone
  • Deferasirox